NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
6.35
-0.37 (-5.51%)
At close: Sep 18, 2026, 4:00 PM EDT
6.30
-0.05 (-0.79%)
After-hours: Sep 18, 2026, 7:30 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
11.74M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Enlivex | 34 |
| Daré Bioscience | 24 |
| CalciMedica | 15 |
| BioVie | 13 |
| AEON Biopharma | 8 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
NRSN News
- 8 days ago - Neurosense Therapeutics Ltd trading halted, news pending - TheFly
- 9 days ago - NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 16 days ago - NeuroSense initiated with a Buy at H.C. Wainwright - TheFly
- 19 days ago - NeuroSense announces redesigned development plan for PrimeC - TheFly
- 19 days ago - NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - PRNewsWire
- 5 weeks ago - NeuroSense Issues CEO Letter to Shareholders - PRNewsWire
- 6 weeks ago - NeuroSense sees December 2026 as filing date for NDS for PrimeC - TheFly
- 6 weeks ago - NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - PRNewsWire